Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy

 In Press Releases

BASEL, Switzerland – 15th March 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new translational data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma has been accepted for presentation in a Late-Breaking session at the 2023 American Association for Cancer Research (AACR) Annual Meeting. AACR will be held in person in Orlando, FL from 14th to 19th April.

Poster Presentation Details:

  • Title: NOUS-PEV, a Personalized Cancer Immunotherapy targeting neoantigens, induces long lasting, tumor infiltrating memory T cells
  • Session Title: Late-Breaking Research: Clinical Research 2
  • Date & Time: 18th April 2023, 9:00 AM – 12:30 PM EDT
  • Location: Poster Section 35, Poster Board 11
  • Poster Number: LB196
  • Presenter: Dr. Elisa Scarselli, Chief Scientific Officer at Nouscom

The full abstract will be available on 14th April 2023 at 12pm EDT.

Recent Posts
error: Content is protected !!!